CUSIP No. 344174 10 7
Flagship Fund V directly holds 9,330,878 shares of Common Stock. Flagship Fund V GP, as the general partner of Flagship Fund V, may be deemed to beneficially own the shares directly held by Flagship Fund V.
Flagship Opportunities Fund I directly holds 1,491,441 shares of Common Stock. Flagship Opportunities Fund I GP, as the general partner of Flagship Opportunities Fund I, may be deemed to beneficially own the shares directly held by Flagship Opportunities Fund I.
Flagship Opportunities Fund II may be deemed to beneficially own 3,666,715 shares of Common Stock, consisting of (i) 1,851,801 shares of Common Stock and (ii) 1,814,914 shares of Common Stock underlying warrants that are currently exercisable. Flagship Opportunities Fund II GP, as the general partner of Flagship Opportunities Fund II, and Flagship Pioneering, as the manager of Flagship Opportunities Fund II GP, may be deemed to beneficially own the shares beneficially owned by Flagship Opportunities Fund II.
Flagship Fund VII may be deemed to beneficially own 1,814,915 shares of Common Stock underlying warrants that are currently exercisable. Flagship Fund VII GP, as the general partner of Flagship Fund VII, and Flagship Pioneering, and the manager of Flagship Fund VII GP, may be deemed to beneficially own the shares beneficially owned by Flagship Fund VII.
Dr. Afeyan, as the sole manager of Flagship Fund V GP and Flagship Opportunities Fund I GP, and as CEO, sole shareholder and director of Flagship Pioneering, may be deemed to beneficially own the shares directly held by the Flagship Funds.
(c) On May 22, 2024, pursuant to an underwritten public offering of the Issuer (the “May 2024 Public Offering”), Flagship Opportunities Fund II and Flagship Fund VII purchased 1,814,914 pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”) and 1,814,915 Pre-Funded Warrants, respectively, for a price per Pre-Funded Warrant of $5.5099.
ITEM 6. | CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER |
Pre-Funded Warrants
On May 22, 2024, pursuant to the May 2024 Public Offering, Flagship Opportunities Fund II and Flagship Fund VII purchased 1,814,914 Pre-Funded Warrants and 1,814,915 Pre-Funded Warrants, respectively, for a price per Pre-Funded Warrant of $5.5099. The Pre-Funded Warrants are immediately exercisable and do not expire; provided, however, that the holder will not be entitled to exercise any portion of any Pre-Funded Warrants that, upon giving effect to such exercise, would cause: (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) to exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Issuer’s securities beneficially owned by such holder (together with its affiliates) to exceed 9.99% of the combined voting power of all Issuer securities outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. However, any holder of a Pre-Funded Warrant may increase or decrease such percentage to any other percentage not in excess of 19.99% upon at least 61 days’ prior notice delivered from the holder to the Issuer.
Lock-Up Agreements
In connection with the May 2024 Public Offering, the Flagship Funds entered into lock-up agreements (the “Lock-Up Agreements”) with the underwriters under which they have agreed that for a period of 60 days following May 20, 2024, without the prior written consent of the representatives, they will not, and will not cause or direct any of their affiliates to, (i) offer, sell, contract to sell, pledge, grant any option to purchase, lend or otherwise dispose of any Common Stock or such other securities, (ii) engage in any hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other